Cancer vaccine in India

Bagchi, Sanjit
January 2006
CMAJ: Canadian Medical Association Journal;1/17/2006, Vol. 174 Issue 2, p151
Academic Journal
The article reports on the plans of the Indian government to introduce a vaccine in 2006 that aims to control cervical cancer. Information on cervical cancer is also given. It also provides information on how Indian women lacks awareness of the disease. Completion of the clinical trials of the vaccine is also mentioned.


Related Articles

  • Human Papilloma Virus Vaccination: Recent Trends in Prevalence and Recommendations in India. Patel, Megha Snehal; Kakkad, Khyati Mitesh; Patel, Snehal Vitthalbhai // Journal of the South Asian Federation of Menopause Societies;Jan-Jun2014, Vol. 2 Issue 1, p26 

    Cervical cancer, mainly caused by human papilloma virus (HPV) infection, is the leading cause of cancer mortality and morbidity in Indian women. Vaccination being the most effective preventive option, and with the availability of two vaccines, quarries and controversies have stirred much debate...

  • Two Doses of HPV Vaccine May Be Sufficient. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;10/19/2011, Vol. 306 Issue 15, p1643 

    The article reports on the adequacy of two doses of a human papillomavirus (HPV) vaccine to protect against cervical cancer based on a clinical trial in Costa Rica conducted by Aimée R. Kreimer et al. published in the "Journal of the National Cancer Institute" in 2011.

  • New vaccine on trial. Marinos, Sarah // Good Medicine (Australian Consolidated Press);Nov2002, p34 

    Provides information on a study which dealt with vaccine testing for the prevention of cervix cancer. Clinical trial at the Royal Women's Hospital in Melbourne, Australia; Feasibility of the vaccine; Gynecological examination requirements.

  • Therapeutic vaccination for HPV induced cervical cancers. Brinkman, Joeli A.; Hughes, Sarah H.; Stone, Pamela; Caffrey, Angela S.; Muderspach, Laila I.; Roman, Lynda D.; Weber, Jeffrey S.; Kast, W. Martin // Disease Markers;2007, Vol. 23 Issue 4, p337 

    Cervical Cancer is the second leading cause of cancer – related deaths in women worldwide and is associated with Human Papillomavirus (HPV) infection, creating a unique opportunity to treat cervical cancer through anti-viral vaccination. Although a prophylactic vaccine may be available...

  • WHO consultation on human papillomavirus vaccines.  // Weekly Epidemiological Record;9/2/2005, Vol. 80 Issue 35, p299 

    The article presents information about human papillomavirus (HPV) vaccines. The peak incidence of HPV infection occurs in adolescents and young women under 25 years of age. Vaccines against HPV infections have the potential to be a more practical and cost-effective way to reduce the incidence of...

  • HPV 16/18 PROPHYLACTIC CERVICAL CANCER VACCINE: DEVELOPMENT UPDATE. Bock, Hans // Infectious Diseases in Obstetrics & Gynecology;2006, Vol. 2006, p13 

    Rationale for development. HPV types 16 and 18 are most frequently associated with cervical cancer, occurring in > 70% cases globally [72]. In some locations (the Philippines, Costa Rica, Bangkok), the odds ratio associating HPV and cervical cancer is > 10 times that of cigarette smoking and...

  • An Analysis of HPV Vaccine Efficacy in Preventing Cervical Cancer. Ershler, William B. // Clinical Oncology Alert;Jul2007, Vol. 23 Issue 7, p49 

    CERVICAL CANCER CONTINUES TO BE THE SECOND LEADING cause of cancer-related death in women under 45 years of age, resulting in more than 200,000 deaths per year worldwide. It has been well established that a significant majority of these cancers (approximately 70%) are caused by Human Papilloma...

  • CLINIC ROUNDUP.  // BioWorld Today;4/18/2007, Vol. 18 Issue 75, p10 

    The article offers clinical trial updates in the U.S. Advaxis Inc. has finished dosing the third batch of cervical cancer patients involved in its Phase I/II trial of its modified Listeria-based live vaccine called Lovaxin C. Based on data from a Phase II trial of Ostarine conducted by GTx Inc.,...

  • Prevalence of Oncogenic HPY Types in Sardinia (Italy): Implications for the Impact of Prophylactic Anti-HPV Vaccines. Montisci, Stefania; Pitzalis, Sabrina; Greco, Marianna; Orani, Alberto; Rais, Marco; Laconi, Sergio // American Journal of Infectious Diseases;2007, Vol. 3 Issue 3, p134 

    Infection with high-risk HPV genotypes is considered an essential step in cervical carcinogenesis. Recently, prophylactic anti-HPV vaccines have shown to provide effective protection in clinical trials. However, protection appears to be type-restricted, thus, its real extent will depend on HPV...

  • Cervical cancer breakthrough.  // European Pharmaceutical Executive;Nov/Dec2005, p12 

    The article reports that an investigational vaccine from Merck & Co. Inc. has been shown to be 100 percent effective against two virus strains which cause the most incidences of cervical cancer. The phase III trial found that Gardasil prevents high-grade cervical pre-cancers and non-invasive...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics